GlobalData on MSN21 小时
Japan’s MHLW approves CSL Behring’s Andembry to stop HAE attacks
CSL Behring KK has gained approval from Japan's Ministry of Health, Labour and Welfare (MHLW) to manufacture and market ...
PharmaTimes8 天
Andembry treatment approved across Europe
Global biotechnology leader CSL has announced that the European Commission (EC) has approved ANDEMBRY (garadacimab), the ...
Medscape22 天
Angioedema in Heart Failure: Occurrence With ACE Inhibitors and Safety of Angiotensin ...
Angioedema is a well-known side effect of treatment with an angiotensin-converting enzyme (ACE) inhibitor and one that we have been willing to accept in view of the incidence of the problem and ...
PMLiVE7 天
EC approves CSL’s Andembry to prevent hereditary angioedema attacks
The European Commission (EC) has approved CSL’s Andembry (garadacimab) to prevent attacks of hereditary angioedema (HAE) in ...